Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 183 | 183 | 159 | 187 | 206 | 245 | 220 | 258 | 463 | 487 | |
| COGS | — | -125 | -109 | -136 | -152 | -161 | 43 | 156 | 307 | 284 |
| Gross profit | — | — | — | — | — | — | 177 | 103 | 156 | 203 |
| 170 | 294 | 256 | 311 | 340 | 368 | 157 | 75 | 102 | 126 | |
| 14 | 14 | 12 | 12 | 17 | 38 | 19 | 28 | 54 | 77 | |
| OPM % | 7.4% | 7.9% | 7.3% | 6.3% | 8.1% | 15.5% | 8.9% | 10.8% | 11.6% | 15.9% |
| Depreciation | — | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 7 |
| Interest | 0 | 0 | — | 0 | 0 | 0 | 1 | 4 | 1 | 1 |
| 3 | 3 | 4 | 5 | 5 | 7 | 12 | 13 | 17 | 31 | |
| Profit before tax | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 32 | 65 | 101 |
| Tax | 6 | 5 | 3 | 2 | 3 | 12 | 7 | 8 | 16 | 25 |
| Tax % | 35.5% | 33.6% | 28% | 12.5% | 17.5% | 28.4% | 25.1% | 25.6% | 24.4% | 24.4% |
| 10 | 11 | 9 | 11 | 14 | 29 | 20 | 24 | 49 | 76 | |
| PAT margin % | 5.7% | 5.8% | 5.5% | 5.9% | 6.9% | 11.9% | 9% | 9.1% | 10.6% | 15.6% |
| EPS (₹) | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.4 | — | 0.3 | 0.6 | 0.8 |
| EPS adjusted (₹) | — | — | — | — | — | — | — | 0.3 | 0.5 | 0.8 |
| 15.4% | 12.5% | 0% | 0% | 0% | 0% | — | 0% | 0% | 12.3% | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 94 | 94 | 94 |
| Reserves | 192 | 246 | 318 |
| 72 | 4 | 1 | |
| 33 | 66 | 116 | |
| Total equity & liabilities | 392 | 410 | 529 |
| 72 | 78 | 90 | |
| CWIP | 0 | 0 | 0 |
| Investments | 114 | 140 | 202 |
| 206 | 192 | 237 | |
| Total assets | 392 | 410 | 529 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| -2 | 16 | -6 | 23 | 58 | |
| -75 | -27 | 84 | -18 | -51 | |
| 72 | 8 | -15 | -68 | -3 | |
| Net cash flow | -5 | -2 | 63 | -63 | 4 |
| Free cash flow | — | — | -14 | 13 | 47 |
| CFO / Operating profit % | -5.5% | 83.9% | -21.3% | 43.6% | 75.6% |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharmaceuticals Drugs & Formulations | 512.74 | 98.66 | 435.18 | 115.23 | 319.95 | 30.84 |
| Renting of Property | 3.7 | 3 |
| 93.42 |
| 1.68 |
| 91.74 |
| 3.27 |
| Trading of Commodities | 1.1 | -0.03 | 0.67 | 0.04 | 0.63 | -4.76 |
₹ crore by fiscal year